Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Year: 2020
Type: article
Source: Blood
Institutions: Winship Cancer Institute, Emory University, Emory Eye Center, University of Maryland, Baltimore, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Utah, Huntsman Cancer Institute, University College London Hospitals NHS Foundation Trust, Moorfields Eye Hospital NHS Foundation Trust, NIHR Moorfields Biomedical Research Centre, University College London, GlaxoSmithKline (United States), Massachusetts Eye and Ear Infirmary, Harvard University, University of Chicago Medical Center
Language: English
Topic: Drug-Induced Ocular Toxicity
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3094809299